NK012
NK012is a 'nanodevice' formulation ofSN-38(anirinotecanmetabolite). NK012 is an SN-38-releasingpolymeric micelleconstructed by covalently attaching SN-38 to theblock copolymerPEG-PGlu,followed by self-assembly ofamphiphilicblock copolymers in aqueous media.[1] [2]
It has completed phase II clinical trials fortriple-negative breast cancerand relapsedsmall cell lung cancer.[3]In 2016,Nippon Kayakureceivedorphan drugdesignation for NK012 from theUS FDA.[4]This means that if it is approved in the United States, Nippon Kayaku will be entitled to 7 years of market exclusivity. This is intended to incentivize future development, but does not mean the drug has been approved.[citation needed]
See also
[edit]References
[edit]- ^"NCI Drug Dictionary".National Cancer Institute.2011-02-02.Retrieved2020-11-28.
- ^Sumitomo; et al. (2008)."Novel SN-38–Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression".Cancer Research.68(6): 1631–1635.doi:10.1158/0008-5472.CAN-07-6532.PMID18339841.
- ^"Search of: NK012 - List Results - ClinicalTrials.gov".www.clinicaltrials.gov.Retrieved2020-11-28.
- ^Nippon Kayaku Announces FDA Orphan Drug Designation to New Polymeric micelle Anti-Cancer Drug NK012 for Small Cell Lung Cancer. (2016). Evaluategroup.com. Retrieved 24 November 2017, fromhttp://www.evaluategroup.com/Universal/View.aspx?type=Story&id=644017
 | Thisantineoplasticorimmunomodulatorydrugarticle is astub.You can help Wikipedia byexpanding it. |